BioCentury
ARTICLE | Clinical News

Xerecept corticorelin: Phase I/II started

May 10, 2010 7:00 AM UTC

Celtic began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate 10, 20, 30 and 40 µg/kg subcutaneous Xerecept given twice daily in up to 60 pediatric patients. Celtic acquired exclusive...